Cytokinetics

About Cytokinetics

Cytokinetics is a late-stage biopharmaceutical company focused on developing potential medicines to improve the lives of people with debilitating diseases related to muscle dysfunction. Their mission is to enhance healthspan for patients with conditions of impaired muscle function, including cardiovascular and neuromuscular diseases, with a commitment to patient-centric innovation.

Products & Services

Muscle Activators and Inhibitors:A robust pipeline of small molecule drugs aimed at addressing diseases characterized by compromised muscle function, such as heart failure, hypertrophic cardiomyopathy (HCM), and neuromuscular diseases.

Cardiac Myosin Inhibitor:A potential treatment for hypertrophic cardiomyopathy, with clinical trials including SEQUOIA-HCM and MAPLE-HCM, and a New Drug Application accepted by the FDA in 2024.

Specialties

Muscle Biology Cardiovascular Disease Treatment Neuromuscular Disease Treatment Hypertrophic Cardiomyopathy (HCM) Research Heart Failure Treatment muscle biology small molecule muscle activators small molecule muscle inhibitors heart failure therapeutics hypertrophic cardiomyopathy therapeutics neuromuscular disease therapeutics

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Public Offering T: - FT: Public Offering	A: 805000000 MR: - FA: approximately $805 million FAN: 805000000	D: 2026-05-08 FD: 2026-05-08	9 investors
2	RT: Public Offering T: - FT: Public Offering	A: 700000000 MR: - FA: approximately $700 million FAN: 700000000	D: 2026-05-06 FD: 2026-05-06	9 investors
3	RT: Public Offering T: - FT: Public Offering	A: 650000000 MR: - FA: approximately $650 million FAN: 650000000	D: 2026-05-05 FD: 2026-05-05	4 investors
4	RT: Convertible Debt T: - FT: Convertible Debt	A: 550000000 MR: - FA: $550.0 million FAN: 550000000	D: 2025-09-16 FD: 2025-09-16	-
5	RT: Debt T: - FT: Debt	A: 650000000 MR: - FA: $650.0 million FAN: 650000000	D: 2025-09-16 FD: 2025-09-16	-
6	RT: Public Offering T: - FT: Public Offering	A: 500000000 MR: - FA: approximately $500 million FAN: 500000000	D: 2024-05-28 FD: 2024-05-28	3 investors
7	RT: Strategic Funding Collaboration T: - FT: Strategic Funding Collaboration	A: 575000000 MR: - FA: up to $575 million FAN: 575000000	D: 2024-05-22 FD: 2024-05-22	1 investors
8	RT: Public Offering of Common Stock T: - FT: Public Offering of Common Stock	A: 500000000 MR: - FA: $500 million FAN: 500000000	D: 2024-05-22 FD: 2024-05-22	3 investors
9	RT: Public Offering T: - FT: Public Offering	A: 500000000 MR: - FA: approximately $500 million FAN: 500000000	D: 2024-05-22 FD: 2024-05-22	3 investors
10	RT: Strategic Collaboration T: - FT: Strategic Collaboration	A: 575000000 MR: - FA: up to $575 million FAN: 575000000	D: 2024-05-22 FD: 2024-05-22	1 investors

Public Offering Latest

2026-05-08

$805.0M

9 investors (Pro only)

Public Offering 2026-05-06

$700.0M

Public Offering 2026-05-05

$650.0M

View 9 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

J

James Sabry

J

James Spudich

R

Ronald Vale

L

Lawrence S.B. Goldstein

View 1 more team members with Pro

Unlock Full Team Directory

Recent News

Cytokinetics Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised